New therapeutics in systemic lupus erythematosus

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

(2012) Susan Manzi et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial

(2012) Zhi-Wei Lai et al.   ARTHRITIS AND RHEUMATISM

Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: The potential role for regulatory T cells

(2012) Haiyan Tu et al.   ATHEROSCLEROSIS

Systemic Lupus Erythematosus, Progressive Multifocal Leukoencephalopathy, and T-CD4+ Lymphopenia

(2012) Mariana Brandão et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Belimumab: Review of Use in Systemic Lupus Erythematosus

(2012) Eric G. Boyce et al.   CLINICAL THERAPEUTICS

Belimumab for the management of systemic lupus erythematosus

(2012) Pamela M K Lutalo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Abatacept in the treatment of lupus

(2012) Alberta Y. Hoi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Abatacept for systemic lupus erythematosus: the outlook

(2012) Chi Chiu Mok   EXPERT OPINION ON BIOLOGICAL THERAPY

Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus

(2012) T. Koga et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis

(2012) Lan Lan et al.   Journal of Zhejiang University-SCIENCE B

Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study

(2012) A Fernández-Nebro et al.   LUPUS

Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice

(2012) RA Stirzaker et al.   LUPUS

Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health

(2012) CB Casella et al.   LUPUS

Selective APRIL Blockade Delays Systemic Lupus Erythematosus in Mouse

(2012) Bertrand Huard et al.   PLoS One

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

Belimumab and the Clinical Data

(2012) Katrina Shum et al.   Current Rheumatology Reports

Use of atorvastatin in systemic lupus erythematosus in children and adolescents

(2011) L. E. Schanberg et al.   ARTHRITIS AND RHEUMATISM

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice

(2011) Chaim O. Jacob et al.   ARTHRITIS AND RHEUMATISM

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

(2011) H. Travis Ichikawa et al.   ARTHRITIS AND RHEUMATISM

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

(2011) Cándido Díaz-Lagares et al.   AUTOIMMUNITY REVIEWS

Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus

(2011) Dilip Shah et al.   FREE RADICAL RESEARCH

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE

(2011) Matthew M. Seavey et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

IL-17-producing T cells in lupus nephritis

(2011) SA Apostolidis et al.   LUPUS

Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q

(2011) CC Mok et al.   LUPUS

The role of BsmI and FokI vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D in Brazilian patients with systemic lupus erythematosus

(2011) OA Monticielo et al.   LUPUS

Systemic Lupus Erythematosus

(2011) George C. Tsokos   NEW ENGLAND JOURNAL OF MEDICINE

Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV

(2010) Kunihiro Ichinose et al.   ARTHRITIS AND RHEUMATISM

T cells as therapeutic targets in SLE

(2010) José C. Crispín et al.   Nature Reviews Rheumatology

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Activation of Mammalian Target of Rapamycin Controls the Loss of TCR  in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation

(2009) D. R. Fernandez et al.   JOURNAL OF IMMUNOLOGY

Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients

(2009) MA Rabbani et al.   LUPUS

Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine

(2009) Enrique Montero et al.   VACCINE

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM